Company intelligence / Profile preview

Dako

Ownership: Private
Employees: ~1200
Development stage: Commercial

Overview

Dako is a pioneer in tissue-based cancer diagnostics, best known for developing the first FDA-approved companion diagnostic (HercepTest) for HER2 in breast and gastric cancer, and for its widely used pathology automation instruments and antibody reagents. Acquired by Agilent Technologies in 2012, its products are globally commercialized and used in routine clinical practice[1][2][3][5].

Therapeutic areas: Oncology
Modalities: AntibodyProteinDiagnostic test
Industry: Protein Biomarker Diagnostics

Partnerships

Eli Lilly and Company (companion diagnostics development)[5]Genentech (Herceptin + HercepTest companion diagnostic)[1]Tecan Group (OEM hardware development for Dako instruments)[7]

Beyond the preview

Go deeper on Dako.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dako.

Explore the full profile